Association of COVID-19 with acute and post-acute risk of multiple different complications and mortality in patients infected with omicron variant stratified by initial disease severity: a cohort study in Hong Kong
The risk of multiple different disease outcomes in both acute and post-acute phases increased significantly with the increasing severity of acute COVID-19 illness, specifically among the elderly. Moreover, future studies could improve by risk-stratifying patients based on universally accepted thresholds for clinical parameters, particularly biomarkers, using biological evidence from immunological studies.
Authors
- Chak Sing Lau (ORCID: https://orcid.org/0000-0001-6698-8355)
- Celine Sze Ling Chui (ORCID: https://orcid.org/0000-0003-1513-8726)
- Eric Yuk Fai Wan (ORCID: https://orcid.org/0000-0002-6275-1147)
- Esther W. Chan (ORCID: https://orcid.org/0000-0002-7602-9470)
- Carlos King Ho Wong (ORCID: https://orcid.org/0000-0002-6895-6071)
- Francisco Tsz Tsun Lai (ORCID: https://orcid.org/0000-0002-9121-1959)
- Vincent Ka Chun Yan (ORCID: https://orcid.org/0000-0001-5225-3032)
- Ian Chi Kei Wong (ORCID: https://orcid.org/0000-0001-8242-0014)
- Sukriti Mathur (ORCID: https://orcid.org/0000-0001-6261-5674)
- Xue Li (ORCID: https://orcid.org/0000-0003-4836-7808)
- Ran Zhang (ORCID: https://orcid.org/0009-0006-2431-5615)
Institutions
- Aston University (GB)
- Chinese University of Hong Kong (HK)
- Hong Kong Science and Technology Parks Corporation (HK)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- HKU-Pasteur Research Pole (HK)
- The London College (GB)
- Laboratory of Data Discovery for Health (HK)
- University College London (GB)
- University of Hong Kong (HK)
Publication Details
- Journal
- BMC Medicine
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1186/s12916-024-03630-6
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- National Institute for Health and Care Research
- European Commission
- National Natural Science Foundation of China
- Innovation and Technology Commission
- Hong Kong Government
- Medical Research Council
- National Health and Medical Research Council
- Health and Medical Research Fund